The FDA has granted SpinaFX Medical an Investigational Device Exemption (IDE) to launch a pivotal U.S. clinical trial testing Triojection, a minimally invasive ozone and oxygen injection treatment for patients with herniated lumbar discs that have failed conservative therapy. The randomized controlled trial will enroll 300 patients across up to 30 specialty spine treatment sites to determine whether adding intradiscal ozone/oxygen injection to conventional nerve root block treatment improves pain and functional outcomes compared to nerve root block alone.

What Is the Therapeutic Gap in Disc Herniation Treatment?

Herniated discs represent a significant unmet clinical need in spine care. Currently, patients face a stark choice: pursue conservative treatments like physical therapy and injections, or undergo surgery. Leaders in interventional spine care have long argued for more minimally invasive, image-guided options that fall between these two extremes. This gap is where Triojection aims to fit.

Contained disc herniation affects millions of patients globally each year and carries substantial healthcare costs. The condition occurs when the inner material of a spinal disc bulges outward but remains contained within the disc's outer layer, often causing nerve compression and pain. Many patients exhaust conservative treatments without adequate relief, yet may not be candidates for or willing to undergo surgery.

How Does the Triojection Trial Work?

The prospective, randomized, multicenter trial is designed with two treatment arms to rigorously evaluate the therapy's safety and effectiveness. Here's what the study will measure:

• Study Design: Patients will be randomly assigned to receive either intradiscal ozone/oxygen injection plus nerve root block, or nerve root block alone, ensuring unbiased comparison of outcomes.
• Patient Population: The trial will enroll 300 participants with contained herniated lumbar discs who have already failed conservative therapy, representing the exact population most likely to benefit.
• Follow-up Duration: Researchers will measure pain and functional outcomes at 6, 12, 18, and 24 months to assess both short-term and long-term effectiveness.
• Economic Analysis: The study will also evaluate the cost-effectiveness of adding Triojection to conventional treatments, helping determine whether the added benefit justifies the additional expense.
• Site Coordination: Site and core laboratory partnerships are currently under discussion to ensure consistent data quality and study execution across all 30 participating centers.

This rigorous trial design reflects FDA standards for breakthrough device evaluation. The IDE approval represents a significant regulatory milestone, as it permits the company to proceed with human testing in the United States.

Why Is This Treatment Considered a Breakthrough?

Triojection received FDA Breakthrough Device Designation in August 2025, a status reserved for technologies that show promise in addressing serious conditions with unmet clinical needs. While intradiscal ozone therapy has been used in certain markets outside the United States, the U.S. pivotal trial will be the first rigorous evaluation of its safety and effectiveness in an American clinical setting.

"This IDE is another major milestone for SpinaFX, years in the making. My European colleagues and I have been extensively involved in the clinical development and refinement of intradiscal ozone in Europe and Canada. While this approach has been used in certain markets outside the United States, the U.S. pivotal trial is intended to evaluate its safety and effectiveness in a rigorous clinical setting and to help determine whether it may become an additional minimally invasive option for appropriately selected patients in the USA," said Prof. Kieran Murphy, Interventional Neuroradiologist at Toronto Western Hospital and Co-Founder and Chief Medical Officer of SpinaFX Medical.

Prof. Kieran Murphy, Interventional Neuroradiologist at Toronto Western Hospital, Co-Founder and Chief Medical Officer of SpinaFX Medical

Published literature cited by SpinaFX reports encouraging clinical findings for intradiscal ozone therapy outside the United States, and meta-analysis of other investigators' work provides background support for further investigation. However, the therapy remains investigational in the United States, and any regulatory approval, clinical adoption, or commercial availability will depend entirely on the results of this pivotal trial and subsequent FDA review.

What Happens Next?

The IDE approval permits SpinaFX to initiate patient enrollment at the participating specialty spine treatment centers. The company is currently working to finalize site and laboratory partnerships to support trial execution. If the trial demonstrates that Triojection significantly improves pain and function compared to nerve root block alone, SpinaFX would be positioned to submit a marketing authorization application to the FDA.

For the millions of patients with herniated discs who have exhausted conservative options, this trial represents a potential new pathway between failed conservative care and surgery. The results will determine whether ozone-based intradiscal injection becomes a standard minimally invasive treatment option in the United States.